OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Rhea-AI Summary

RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma on Bloomberg TV on August 10, 2024, at 7 p.m. ET. Paul Romness, Chairman and CEO of OS Therapies, will provide a corporate update on the company's novel treatments for Osteosarcoma and other solid tumors. OS Therapies' product candidates, OST-HER2 and OST-tADC, aim to address gaps in pediatric and young adult cancer care. The company is approaching significant clinical milestones and potential revenue streams, including out-licensing deals and a priority review voucher valued at $100-110M.

Positive

• OS Therapies is developing novel treatments for Osteosarcoma and other solid tumors
• The company is approaching major clinical milestones
• Potential near-term revenue streams from out-licensing deals: canine OS ($15M+), human OS ($100M+), and OST-tADC SiLinkers™ ($20-80M)
• Priority review voucher valued at $100-110M adds another potential revenue source

Negative

• None.

ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• OS Therapies: https://www.redchip.com/assets/access/ostx_access

• Can-Fite: https://www.redchip.com/assets/access/canf_access

In an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. OS Therapies stands out in the biopharma landscape with its dedicated mission to develop novel treatments for Osteosarcoma (OS) and other solid tumors. Through its innovative product candidates, OST-HER2 and OST-tADC, the company is not only addressing a significant gap in pediatric and young adult cancer care but also expanding its therapeutic reach to a broader range of solid tumors. As it advances through clinical stages, OS Therapies could significantly alter the trajectory of cancer treatment for a demographic long in need of breakthrough therapies. OS Therapies is on the verge of major clinical milestones and is poised to potentially generate revenues from multiple streams: out-licensing deals for canine OS ($15M+), human OS ($100M+), and OST-tADC SiLinkers™ ($20-80M) represent near-term revenue potential. A priority review voucher, valued at between $100-110M adds another layer of potential revenue.

Motti Farbstein, CEO of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Can-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company has two drug candidates in advanced stages of development, Piclidenoson for the treatment of psoriasis and Namodenoson for the treatment of advanced liver cancer. For each of the drugs, a registration plan has been agreed with both the U.S. FDA and the European Medicines Agency (EMA) and enrollment of patients for a pivotal Phase III clinical study is ongoing for liver cancer and underway for psoriasis. Namodenoson also has a robust anti-cancer effect against pancreatic cancer and a Phase IIa clinical study will be initiated in Q2 2024. Due to the liver-protective effect of Namodenoson, a Phase IIb study for the treatment NASH (MASH) is currently enrolling patients. Piclidenoson and Namodenoson have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment metabolic dysfunction-associated steatohepatitis (MASH), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.canfite.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com

--END--

SOURCE: RedChip

View the original press release on accesswire.com

FAQ

What are OS Therapies' (OSTX) main product candidates?

OS Therapies' main product candidates are OST-HER2 and OST-tADC, which are being developed for Osteosarcoma and other solid tumors.

When will the OS Therapies (OSTX) interview air on Bloomberg TV?

The OS Therapies interview will air on Bloomberg TV on August 10, 2024, at 7 p.m. Eastern Time.

What are the potential revenue streams for OS Therapies (OSTX)?

OS Therapies has potential revenue streams from out-licensing deals for canine OS ($15M+), human OS ($100M+), OST-tADC SiLinkers™ ($20-80M), and a priority review voucher valued at $100-110M.

What is the focus of OS Therapies' (OSTX) drug development?

OS Therapies focuses on developing novel treatments for Osteosarcoma (OS) and other solid tumors, particularly addressing gaps in pediatric and young adult cancer care.